HC Wainwright Issues Positive Estimate for RCUS Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for Arcus Biosciences in a report issued on Thursday, August 6th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($1.00) per share for the quarter, up from their previous estimate of ($1.07). HC Wainwright has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.60) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q4 2026 earnings at ($0.96) EPS, FY2026 earnings at ($4.35) EPS, FY2027 earnings at ($3.23) EPS, FY2028 earnings at ($2.18) EPS, FY2029 earnings at ($1.45) EPS and FY2030 earnings at ($0.61) EPS.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.17. The company had revenue of $41.00 million for the quarter, compared to analysts’ expectations of $21.98 million. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%.The business’s revenue for the quarter was down 74.4% on a year-over-year basis.

A number of other research analysts also recently commented on the stock. The Goldman Sachs Group reaffirmed a “buy” rating and set a $42.00 price objective on shares of Arcus Biosciences in a research report on Friday. Truist Financial assumed coverage on shares of Arcus Biosciences in a research report on Monday, May 18th. They issued a “buy” rating and a $35.00 target price for the company. Leerink Partners set a $47.00 target price on shares of Arcus Biosciences in a research note on Monday, April 20th. Wedbush boosted their price target on shares of Arcus Biosciences from $41.00 to $43.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Wells Fargo & Company boosted their price target on shares of Arcus Biosciences from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $37.80.

Arcus Biosciences Price Performance

NYSE RCUS opened at $28.68 on Monday. The company has a 50 day simple moving average of $27.45 and a 200-day simple moving average of $24.32. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.82 and a quick ratio of 3.82. The firm has a market capitalization of $3.65 billion, a price-to-earnings ratio of -7.35 and a beta of 0.80. Arcus Biosciences has a 52-week low of $8.88 and a 52-week high of $31.74.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, President Juan C. Jaen sold 20,067 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $28.62, for a total transaction of $574,317.54. Following the completion of the sale, the president owned 822,240 shares of the company’s stock, valued at $23,532,508.80. This represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,562 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $25.77, for a total value of $66,022.74. Following the transaction, the chief accounting officer owned 39,581 shares in the company, valued at approximately $1,020,002.37. This trade represents a 6.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 102,562 shares of company stock valued at $2,975,354. Corporate insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hantz Financial Services Inc. lifted its position in Arcus Biosciences by 121.9% during the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after acquiring an additional 881 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Arcus Biosciences in the fourth quarter valued at about $39,000. KBC Group NV bought a new position in shares of Arcus Biosciences in the first quarter worth about $50,000. Strs Ohio bought a new position in shares of Arcus Biosciences in the first quarter worth about $67,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Arcus Biosciences by 184.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock worth $69,000 after purchasing an additional 5,476 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.